Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 12;13:903599. doi: 10.3389/fphar.2022.903599

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Li, Zhu, Chen, Zhang, Zhang, Zhang, Wang, Jiang, Lin, Wu, Mo, Sze and Yung.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

IATL inhibits HCT116 tumor growth in BALB/c-nu/nu mice. Nude mice were i.p. administered with vehicle control (PBS solution containing 5% PEG400 and 5% Tween80), IATL (10 mg/kg), or IATL (20 mg/kg) daily for 15 consecutive days. Photographs of tumors (A), tumor weights (B), tumor volumes (C) and mouse body weights (D) are shown. Data are presented as mean ± SD of six mice. (E) IATL lowered protein levels of phospho-mTOR (Ser2448), phospho-AKT (Ser473), phospho-70S6K, Bcl-2 and Bcl-XL and upregulated protein levels of cleaved-PARP and LC3B-II in HCT116 xenografts. Immunoblotting for xenografts from three individual mice were performed. Representative immunoblotting bands (left panels) and quantitative results are shown (right panels). Data in bar charts are presented as mean ± SD. **p < 0.01 vs. vehicle control group.